Literature DB >> 20149071

The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics.

K C Gersh1, S Zaitsev, V Muzykantov, D B Cines, J W Weisel.   

Abstract

SUMMARY
BACKGROUND: Coupling fibrinolytic plasminogen activators to red blood cells (RBCs) has been proposed as an effective, yet safe method of thromboprophylaxis, because of increased circulation lifetime and reduced propensity to induce hemorrhage by selectivity for nascent thrombi rather than pre-formed hemostatic clots. OBJECTIVES AND METHODS: We used confocal microscopy of fluorescently labeled fibrin and erythrocytes in plasma-derived clots to study the spatial dynamics of lysis catalyzed by RBC-coupled vs. free plasminogen activators (RBC-PA vs. PA).
RESULTS: Clot lysis catalyzed by free PA progressed gradually and uniformly. In contrast, distinct holes formed surrounding RBC-PA while the rest of the clot remained intact until these holes enlarged sufficiently to merge, causing sudden clot dissolution. Compared with naïve RBCs within clots lysed by free PA, RBC-PA moved faster inside the fibrin network prior to clot dissolution, providing a potential mechanism for spatial propagation of RBC-PA induced lysis. We also showed the focal nature of fibrinolysis by RBC-PA as dense loading of PA onto RBCs initiates more efficient lysis than equal amounts of PA spread sparsely over more RBCs. In an in vitro model of clots exposed to buffer flow, incorporated RBC-PA increased permeability and formed channels eventually triggering clot dissolution, whereas clots containing free PA remained intact.
CONCLUSIONS: Clot lysis by RBC-PA begins focally, has a longer lag phase when measured by residual mass than homogeneous lysis by PA, is propagated by RBC-PA motility and provides more effective clot reperfusion than free PA, making RBC-PA attractive for short-term thromboprophylaxis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20149071      PMCID: PMC2890030          DOI: 10.1111/j.1538-7836.2010.03802.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  20 in total

1.  Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy.

Authors:  J P Collet; D Park; C Lesty; J Soria; C Soria; G Montalescot; J W Weisel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

2.  Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.

Authors:  Juan-Carlos Murciano; Sandra Medinilla; Donald Eslin; Elena Atochina; Douglas B Cines; Vladimir R Muzykantov
Journal:  Nat Biotechnol       Date:  2003-07-06       Impact factor: 54.908

3.  Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots.

Authors:  Jean-Philippe Collet; Claude Lesty; Gilles Montalescot; John W Weisel
Journal:  J Biol Chem       Date:  2003-03-17       Impact factor: 5.157

4.  Blood clearance and activity of erythrocyte-coupled fibrinolytics.

Authors:  Kumkum Ganguly; Tatiana Krasik; Sandra Medinilla; Khalil Bdeir; Douglas B Cines; Vladimir R Muzykantov; Juan Carlos Murciano
Journal:  J Pharmacol Exp Ther       Date:  2004-11-03       Impact factor: 4.030

Review 5.  Molecular mechanisms of fibrinolysis.

Authors:  Gabriela Cesarman-Maus; Katherine A Hajjar
Journal:  Br J Haematol       Date:  2005-05       Impact factor: 6.998

6.  Twisting of fibrin fibers limits their radial growth.

Authors:  J W Weisel; C Nagaswami; L Makowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

Review 7.  Plasminogen activators: a comparison.

Authors:  Dev B Baruah; Rajendra N Dash; M R Chaudhari; S S Kadam
Journal:  Vascul Pharmacol       Date:  2005-11-07       Impact factor: 5.773

Review 8.  Prevention of venous thromboembolism.

Authors:  G P Clagett; F A Anderson; J Heit; M N Levine; H B Wheeler
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

9.  Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.

Authors:  Sergei Zaitsev; Sergei Zaitzev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Khalil Bdeir; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030

10.  Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy.

Authors:  D V Sakharov; J F Nagelkerke; D C Rijken
Journal:  J Biol Chem       Date:  1996-01-26       Impact factor: 5.157

View more
  12 in total

1.  Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent.

Authors:  Kathryn C Gersh; Sergei Zaitsev; Douglas B Cines; Vladimir Muzykantov; John W Weisel
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

2.  Histopathological Characteristics of IV Recombinant Tissue Plasminogen -Resistant Thrombi in Patients with Acute Ischemic Stroke.

Authors:  Adnan I Qureshi; Mushtaq H Qureshi; Iryna Lobanova; Asif Bashir; Asif A Khan; Stephen M Bologna; Michelle Peterson; M Fareed K Suri
Journal:  J Vasc Interv Neurol       Date:  2016-01

Review 3.  Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.

Authors:  Carlos H Villa; Douglas B Cines; Don L Siegel; Vladimir Muzykantov
Journal:  Transfus Med Rev       Date:  2016-08-17

Review 4.  Advanced drug delivery systems for antithrombotic agents.

Authors:  Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

5.  Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.

Authors:  Sergei Zaitsev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Oscar A Marcos-Contreras; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2010-04-21       Impact factor: 22.113

Review 6.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

Review 7.  Non-affinity factors modulating vascular targeting of nano- and microcarriers.

Authors:  Jacob W Myerson; Aaron C Anselmo; Yaling Liu; Samir Mitragotri; David M Eckmann; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2015-10-24       Impact factor: 15.470

Review 8.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

Review 9.  Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.

Authors:  Carlos H Villa; Aaron C Anselmo; Samir Mitragotri; Vladimir Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2016-03-03       Impact factor: 15.470

10.  Intravascular forward-looking ultrasound transducers for microbubble-mediated sonothrombolysis.

Authors:  Jinwook Kim; Brooks D Lindsey; Wei-Yi Chang; Xuming Dai; Joseph M Stavas; Paul A Dayton; Xiaoning Jiang
Journal:  Sci Rep       Date:  2017-06-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.